AChE
Acetylcholinesterase (AChE) is the principal cholinergic enzyme that rapidly hydrolyzes acetylcholine at cholinergic synapses and neuromuscular junctions, thereby terminating neurotransmission and maintaining synaptic signaling fidelity[1]. Mechanistically, AChE regulates cholinergic pathway activity through efficient acetylcholine clearance, a process that is essential for normal neuronal communication and neuromuscular function[1]. Beyond its catalytic role, AChE displays multiple molecular forms and has been implicated in cellular interactions, neuronal activity modulation, and pathological states, supporting broader biological functions outside classical neurotransmission[1]. In neurodegenerative disease models, particularly Alzheimer’s disease (AD), altered cholinergic signaling is closely associated with cognitive impairment, and cholinesterase inhibition remains a major symptomatic therapeutic strategy[2][3]. Compared with the related isoform butyrylcholinesterase (BChE), AChE is the predominant cholinesterase in the brain and plays a primary role in synaptic acetylcholine hydrolysis, whereas BChE may compensate when AChE activity is reduced and exhibits distinct pathological changes during AD progression[3][4]. For experimental and translational applications, reversible and dual AChE/BChE inhibitors, including rivastigmine, are widely used to enhance cholinergic neurotransmission and investigate mechanisms underlying neurodegeneration and cognitive dysfunction[2][3].
References:
- [1]. Massoulié J, et al. Structure and functions of acetylcholinesterase and butyrylcholinesterase. Prog Brain Res. 1993;98:139-46. [Content Brief]
- [2]. Walczak-Nowicka ŁJ, et al. Acetylcholinesterase Inhibitors in the Treatment of Neurodegenerative Diseases and the Role of Acetylcholinesterase in their Pathogenesis. Int J Mol Sci. 2021 Aug 27;22(17):9290. [Content Brief]
- [3]. Nordberg A, et al. A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease. Prim Care Companion CNS Disord. 2013;15(2):PCC.12r01412. [Content Brief]
- [4]. Geula C, et al. Butyrylcholinesterase, cholinergic neurotransmission and the pathology of Alzheimer's disease. Drugs of Today (Barcelona, Spain : 1998). 2004 Aug;40(8):711-721. [Content Brief]
-
AChE Related Products (458)
Related Products (458)
-
AChE-IN-114
0 ImagesCat. No.: HY-185347CAS No.: 2365405-51-0
-
Memoquin
0 ImagesCat. No.: HY-122080CAS No.: 616885-87-1Memoquin is an anti-amyloid and anti-oxidant multi-target-directed ligand. Memoquin is an orally active inhibitor of BACE-1 and AChE with IC50 values of 108 and 1.55 nM, respectively. Memoquin is a cognitive enhancer that prevents the Aβ-induced neurotoxicity mediated by oxidative stress. Memoquin can be used for the research of Alzheimer’s disease (AD).
-
CI-1002
0 ImagesCat. No.: HY-19181CAS No.: 149028-28-4Synonyms: PD 142676CI-1002 (PD 142676) is a potent acetylcholinesterase (AChE) and muscarinic antagonist. CI-1002 can be used for the study of the cognitive dysfunction of Alzheimer's disease (AD).
-
Dimefluthrin
0 ImagesCat. No.: HY-135450CAS No.: 271241-14-6Dimefluthrin is an insecticide. Dimefluthrin exhibits contact toxicity against large red imported fire ant workers. Dimefluthrin undergoes horizontal transfer among red imported fire ant workers, causing secondary mortality in recipient workers. Dimefluthrin is a neurodevelopmental toxicant, which can reduces acetylcholinesterase activity, impairing neurotransmitter.
-
Trimethylammonium chloride-13C3,d9
0 ImagesCat. No.: HY-Y0504SCAS No.: 2483824-12-8Trimethylammonium chloride-13C3,d9 is the 13C3,d9-labeled Trimethylammonium chloride (HY-Y0504). Trimethylammonium chloride (Hegzadesil) is a non-competitive Acetylcholinesterase inhibitor. Trimethylammonium chloride reversibly blocks the deacetylation of acetylcholinesterase.
-
Trimethylammonium chloride-d10
0 ImagesCat. No.: HY-Y0504S1CAS No.: 107766-37-0Synonyms: Hegzadesil-d10; Trimethylamine hydrochloric acid-d10; Trimethylamine monohydrochloride-d10Trimethylammonium chloride-d10 (Hegzadesil-d10) is the d10-labeled Trimethylammonium chloride (HY-Y0504). Trimethylammonium chloride (Hegzadesil) is a non-competitive Acetylcholinesterase inhibitor. Trimethylammonium chloride reversibly blocks the deacetylation of acetylcholinesterase.
-
AChE-IN-17
0 ImagesCat. No.: HY-N10384CAS No.: 460345-17-9AChE-IN-17 (compound 1) is a potent AChE inhibitor with an IC50 value of 28.98 μM. AChE-IN-17 can significantly prevent H2O2-induced PC12 cell death, exhibiting excellent neuroprotective effect. AChE-IN-17 can be used for researching neurodegenerative diseases (NDs).
-
AChE/BuChE-IN-8
0 ImagesCat. No.: HY-181503AChE/BuChE-IN-8 is a dual AChE and BuChE inhibitor, with an AChE IC50 of 1.18 μM, a human AChE Ki of 1.2 μM, and a BuChE IC50 of 2.34 μM. AChE/BuChE-IN-8 acts as an antiproliferative agent and antioxidant, exerts antiproliferative effects on colon cancer cells, scavenges free radicals, and exhibits reducing power. AChE/BuChE-IN-8 can be used in the research of Alzheimer's disease and colorectal adenocarcinoma.
-
CEase-IN-1
0 ImagesCat. No.: HY-143252CAS No.: 2985688-68-2CEase-IN-1 (Compound A1H3) is a potent and selective cholesterol esterase (CEase) inhibitor with an IC50 of 0.36 μM. CEase-IN-1 can be used for the research of hypercholesterolemia.
-
AChE-IN-93
0 ImagesCat. No.: HY-175474AChE-IN-93 (compound 4m) is a potent AchE inhibitor with an IC50 of 29 nM. AChE-IN-93 can be used in Alzheimer's disease research.
-
Trimethylammonium chloride-15N
0 ImagesCat. No.: HY-Y0504S2CAS No.: 108451-51-0Synonyms: Hegzadesil-15N; Trimethylamine hydrochloric acid-15N; Trimethylamine monohydrochloride-15NTrimethylammonium chloride-15N (Hegzadesil-15N) is the 15N-labeled Trimethylammonium chloride (HY-Y0504). Trimethylammonium chloride (Hegzadesil) is a non-competitive Acetylcholinesterase inhibitor. Trimethylammonium chloride reversibly blocks the deacetylation of acetylcholinesterase.
-
AChE-IN-5
0 ImagesCat. No.: HY-144272CAS No.: 3037236-13-5AChE-IN-5 (compound 5) exhibits strong in vitro bioactivity against AChE/5-HT1A/SERT and exhibits good BBB permeability. AChE-IN-5 shows IC50 value 2.29 nM against AChE, EC50 value 58.6 nM against 5-HT1A and IC50 value against SERT. Orally active.
-
ChE/Aβ1-42-IN-1
0 ImagesCat. No.: HY-144388CAS No.: 2761149-22-6ChE/Aβ1-42-IN-1 (compound 28) is a potent ChE and Aβ1-42 aggregation inhibitor with IC50s of 0.062, 0.767 and 1.227 µM for AChE, BuChE and Aβ1-42 aggregation, respectively. ChE/β1-42-IN-1 shows excellent BBB penetration. ChE/Aβ1-42-IN-1 is a potent multi-targeted anti-Alzheimer's agent.
-
NSS-18
0 ImagesCat. No.: HY-180114NSS-18 is a potent and reversible inhibitor of AChE and MAO-B, with IC50 values of 1.53 and 1.51 μM respectively. NSS-18 can inhibit the self-aggregation of Aβ. NSS-18 inhibits the intracellular generation of ROS induced by Aβ. NSS-18 shows a moderate neuroprotective effect against 6-OHDA (HY-B1081)-induced neurotoxicity. NSS-18 can form chelates with metal ions such as Cu²⁺, Fe³⁺, and Zn²⁺, with the strongest chelation being with Cu²⁺. NSS-18 can be used for the study of Alzheimer's disease.
-
BChE-IN-45
0 ImagesCat. No.: HY-179122CAS No.: 425611-45-6BChE-IN-45 (compound 4p) is a competitive (cholinesterase) dual acting inhibitor (Ki = 11.13 μM). BChE-IN-45 has an IC50 of 13.8 μM for BChE and 35.63 μM for AChE. BChE-IN-45 can be used for research on Alzheimer's disease.
-
AChE/BChE-IN-11
0 ImagesCat. No.: HY-N10701CAS No.: 80443-12-5AChE/BChE-IN-11 (compound 1) is a potent is a dual AChE and BChE inhibitor with IC50 values of 70 and 71 μM for AChE and BChE, respectively. AChE/BChE-IN-11 is a natural product that could be isolated from the leaf of artichoke . AChE/BChE-IN-11 can be used in research of Alzheimer’s disease (AD) research.
-
AChE/BuChE-IN-1
0 ImagesCat. No.: HY-144392CAS No.: 84212-49-7AChE/BuChE-IN-1 (Compound 1), a chrysin derivative, is a selective butyrylcholinesterase (BuChE) inhibitor with an IC50 of 0.48 μM. AChE/BuChE-IN-1 inhibits acetylcholinesterase (AChE) with an IC50 of 7.16 μM. AChE/BuChE-IN-1 shows strong scavenging ·OH activities with a IC50 of 0.1674 μM. AChE/BuChE-IN-1 inhibits reactive oxygen species (ROS), Aβ1-42 aggregation (self-, Cu2+-induced, AChE-induced). AChE/BuChE-IN-1 has high BBB permeability and bioavailability and low cell toxicity. AChE/BuChE-IN-1 has the potential for Alzheimer' disease (AD) research.
-
PE154 (solution)
0 ImagesCat. No.: HY-DY1110CAS No.: 1192750-33-6PE154 (solution) is a fluorescent probe that binds to Aβ plaques, as well as a potent fluorescent inhibitor of AChE and BChE, with an IC50 of 280 pM against hAChE and 16 nM against hBChE. PE154 (solution) is applicable for histochemical detection of Aβ plaques in mouse and human brain tissues. PE154 (solution) can be used in research related to Alzheimer's disease.
Solvent and concentration: DMSO: 5 mM
-
Eseramine
0 ImagesEseramine is a weak acetylcholinesterase inhibitor with an IC50 value of 9300 nM. Eseramine is promising for research of diseases involving the regulation of acetylcholinesterase, such as glaucoma, myasthenia gravis, and protection against organophosphate poisoning.
-
AChE/BChE-IN-17
0 ImagesCat. No.: HY-161150CAS No.: 3026229-55-7
